Home
>
National Drug Code (NDC)
>
Rituxan
Rituxan - 50242-051-21 - (rituximab)
Drug Information of Rituxan
| Product NDC: | 50242-051 |
| Proprietary Name: | Rituxan |
| Non Proprietary Name: | rituximab |
| Active Ingredient(s): | 10 mg/mL & nbsp; rituximab |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Rituxan
| Product NDC: | 50242-051 |
| Labeler Name: | Genentech, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA103705 |
| Marketing Category: | BLA |
| Start Marketing Date: | 19971126 |
Package Information of Rituxan
| Package NDC: | 50242-051-21 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-051-21) > 10 mL in 1 VIAL, SINGLE-USE |
NDC Information of Rituxan
| NDC Code | 50242-051-21 |
| Proprietary Name | Rituxan |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-051-21) > 10 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 50242-051 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | rituximab |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 19971126 |
| Marketing Category Name | BLA |
| Labeler Name | Genentech, Inc. |
| Substance Name | RITUXIMAB |
| Strength Number | 10 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] |
